Position:Emeritus Director
PA:Taryn Hastings
Diabetes Trials Unit
Tel: 01865 857240
Email:rury.holman@dtu.ox.ac.uk
ORCID ID0000-0002-1256-874X
Rury Holman trained in medicine at the University of Bristol in the United Kingdom, founded the University of Oxford Diabetes Trials Unit (DTU) in 1985, and was appointed as the first Professor of Diabetic Medicine at the University of Oxford in 1998. He runs an active Translational Research Group undertaking investigator-led early phase trials of novel therapeutic agents, new medical devices and complex interventions. He also designs and runs investigator-led global cardiovascular outcome trials and is currently joint Chair of EXSCEL and TECOS, and Chief Investigator of ACE and UKPDS. In addition, has a major interest in risk prediction and has co-produced the UKPDS Risk Engine and the UKPDS Outcomes Model, which is used by NICE to assess the potential impact of antidiabetic therapies. Professor Holman has received 16 national and international awards and has published over 370 peer-reviewed papers that have been cited more than 66,000 times.
Manuscript
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management
Ni Gao et al.
PharmacoEconomics 2024;42:1017-1028
Manuscript
Estimated glomerular filtration rate slope and risk of primary and secondary major adverse cardiovascular events and heart failure hospitalization in people with type 2 diabetes: An analysis of the EXSCEL trial
Abderrahim Oulhaj et al.
Diabetes Obes Metab. 2024
Manuscript
Post-trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended from 10 to 24 years (UKPDS 91)
Amanda I. Adler et al.
Lancet 2024;404:145-55
Manuscript
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? insights from post-hoc analysis of EXSCEL,
K.M. Gooding et al.
Diabetes Res Clin Pract. 2024;212:111685
Manuscript
Regional variation in cause of death in patients with type 2 diabetes: insights from EXSCEL: Cause of Death in Type 2 Diabetes
Vishal N Rao et al.
Am Heart J. 2024;271:123-135
Manuscript
Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
Pedro Cardoso et al.
Diabetologia 2024;67:822-836